TEST:

CancerVision

TE-WGS enriches the genomic landscape accessible to clinicians, enhancing personalized treatment strategies in precision oncology through comprehensive and actionable genomic profiling.

In addition to comprehensive cancer profiling, Inocras's MRDVision employs the WGS approach for ultra-sensitive, panel-free detection of minimal residual disease (MRD) at the parts-per-million (ppm) level. This workshop explores the clinical integration of Inocras' WGS technology for cancer profiling and MRD detection, demonstrating how our solutions provide actionable insights with broad clinical impact while achieving fast turnaround time and affordability.

"Inocras...released a new study highlighting the clinical validation of its CancerVision Target-Enhanced Whole-Genome Sequencing (TE-WGS). In a head-to-head comparison with Ilumina’s widely-used TSO500, Inocras demonstrated TE-WGS’s ability to match the industry standard for biomarker detection in oncology, while also offering additional insights that enhance clinical understanding."

"Inocras...proudly announces the launch of CancerVision and RareVision, its flagship whole genome diagnostics solutions in solid tumor cancer and rare disease, respectively."

Our integration of tumor-WGS-informed duplex cfDNA sequencing methods significantly enhances the sensitivity of sequencing-based MRD assays, achieving a technical LoD limit of 10-7 for detecting ctDNA in cancer patients. These approaches represent a breakthrough in monitoring MRD in real-world cancer patients.

"Genome Insight...announced today the U.S. launch of CancerVision, their innovative whole genome sequencing (WGS) test designed to provide accurate, timely and medically meaningful insights that collectively guide personalized healthcare decisions."